Regeneus Ltd (ASX: RGS) ABN Interview with John Martin on Progenza and the Platform Technology
John Martin talks on the release of the financial results following the company's significant progress with Japanese partner AGC. John talks about the successful Progenza STEP trial and the granting of a Japanese patent for the company's Progenza platform technology.
Watch John's full interview with ABN Newswire here.
Regeneus achieves major milestones and secures critical Japan collaboration
John Martin, chief executive for Regeneus, speaks with Proactive Investors.
John Martin talks to Andrew Scott, Proactive Investors in London, discussing some of RGS' major achievements of FY17 in particular the critical Japanese collaboration with AGC, positive STEP Phase 1 results and IP protection for Progenza in Japan, which sets RGS up nicely for discussions with potential clinical partners.
Watch John's full video interview with Proactive Investors here.
Regeneus Focused on Developing Adipose - Derived Allogeneic MSC Product W/ Added Secretions
Regeneus is a firm that conducts research and development in adipose-derived cellular therapies for both human and veterinary use. In December 2016 the firm out-licensed the exclusive Japanese manufacturing rights for their adipose-derived allogeneic mesenchymal stem cell (MSC) product, Progenza, to AGC Asahi Glass. In line with this development, the two firms established a joint-venture, Regeneus Japan, in Shibuya, to assist in their search for a commercialisation partner for Progenza in Japan.
On June 9, 2017 Regeneus’ CEO, Mr. John Martin, and the firm’s Head of Licensing and Alliances, Dr. Duncan Thomson, answered some of this newspaper’s questions on their plans for Japan.
Read the full interview with Nikkei BP Japan here.
Regeneus is Solidifying Out-Licensing Partnering and Looking to Commence a Japanese Phase II Trial
Mr. John Martin, CEO of the Australian regenerative medicine venture company, Regeneus, relayed his plan to Japan Chemical Daily to locate an out-license partner for the firm’s Knee Osteoarthritis (OA) cellular therapy. Progenza is garnering interest from a number of companies on the back of Regeneus’ Australian Phase I data, which showed possible disease modifying properties. AGC Asahi Glass already has exclusive manufacturing rights for Progenza in Japan.
Read the full interview with Japan Chemical Daily here.
Regeneus Q2 2017 News Update
Regeneus released our Q2 2017 update newsletter designed to keep our investors and followers of the company up to date with all the company and industry news over the last quarter.
Read our Q2 2017 newsletter here.
Australia, a hotbed for Regenerative Medicine
An increasing number of Japanese and Australian companies are cooperating in the field of regenerative medicine.
Read the full article by Japan Chemical Daily here.
Australia’s Regeneus commences development of manufacturing process for their OA cellular therapy
Regeneus, an Australian regenerative medicine biotech, has commenced preparation (e.g. donor selection, manufacturing process development) for a Japan-based phase II clinical trial of Progenza, their cellular therapy under development for osteoarthritis (OA).
Read the full article by Japan Chemical Daily here.
Regeneus CEO taking part in delegation to Japan
Regeneus (ASX:RGS) CEO John Martin will be participating in Austrade’s business delegation to Japan on April 18 and 19 being led by Australia’s minister for trade, tourism and investments.
Austrade is the Australian government’s export, international education and foreign investment promotion agency.
The two-day mission will showcase leading Australian capabilities in a range of key sectors including regenerative medicine which is an area of particular interest in Japan.
Read the full article by Proactive Investors here.
Regeneus CEO John Martin Talks About the Licensing of Progenza in Japan
Regeneus Ltd (ASX:RGS) is an Australian clinical-stage regenerative medicine company developing a portfolio of innovative cellular therapies targeting significant unmet medical needs in both human and animal health markets.
With the recent announcement of a significant licensing deal with AGC Ltd in Japan, the company is set to build on their platform for the delivery of Progenza to deal with many healthcare issues from arthritis and pain, to genetic disorders.
The Japanese deal means the company is moving quickly into a new stage of growth as explained by CEO John Martin in a video interview.
Read the full article by ABN Newswire via BioSpace here.
Regeneus reports first half-year profit, funded for eighteen months
Regeneus (ASX:RGS) reported a $3.8 million profit in the first half of FY17 after coming off a $3.1 million loss in FY16.
The profit improvement was driven by the receipt of an upfront licence fee from AGC of Japan (TYO:5201) valued at US$5.5 million, which supports an 18 month funding runway.
Read the full article by Proactive Investors here.
Regeneus Hits the Fast Track with Major Japanese Partnership
Regeneus, an Australian regenerative medicine company, has entered into an collaboration with a major Japanese firm to manufacture its stem cell therapy Progenza, a move that may accelerate approval and that has a pair of analysts optimistic about the company's future.
Read the full article by The Life Sciences Report here.
Companies Flocking to Japan for Biotech Deals: CJ Partners' Colin Lee Novick
For the last two years, Japan has been at the forefront of accelerated approval for regenerative medicine products and has seen lots of licensing and contract manufacturing deals and M&A activity. For The Life Sciences Report Tokyo-based Colin Lee Novick, Managing Director of CJ PARTNERS, surveys the landscape, discussing recent tie-ups, the effects of the recently passed 21st Century Cures Act in the U.S., and what may lie ahead.
View the full transcript via The Life Sciences Report here.
Regeneus receives cash payment from Japan partner
The strategic collaboration and licensing agreement recently entered into is for the manufacture, clinical development and commercialisation of Progenza in Japan.
Progenza is a patented off-the-shelf stem cell technology developed for the treatment of knee osteoarthritis and other inflammatory conditions.
Read the full article by Proactive Investors here.
Regeneus enters 2017 backed by transformational Japan deal
Regeneus (ASX:RGS) has a busy 2017 to come, spearheaded by its recent entry into the Japanese market for its Progenza product.
The company entered into a strategic collaboration and licensing agreement for the manufacture, clinical development and commercialisation of Progenza in Japan.
Read the full article by Proactive Investors here.
Regeneus Q4 2016 News Update
Regeneus released our Q4 2016 update newsletter designed to keep our investors and followers of the company up to date with all the company and industry news over the last quarter.
Read our Q4 2017 newsletter here.